Cantor Fitzgerald restated their overweight rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) in a report published on Friday, Benzinga reports. They currently have a $34.00 target price on the biopharmaceutical company’s stock. Several other equities research analysts also recently weighed in on CPRX. TheStreet raised shares of Catalyst Pharmaceuticals from a c+ […]
StockNews.com upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) from a hold rating to a buy rating in a research note issued to investors on Thursday. A number of other brokerages have also recently commented on CPRX. Oppenheimer initiated coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, December 21st. They […]
StockNews.com upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) from a hold rating to a buy rating in a research note released on Thursday morning. Other research analysts also recently issued reports about the company. Citigroup started coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 14th. They set a buy rating […]
Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $22.90 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.